A data-driven look at lab test pricing across the American healthcare system — from hospital chargemaster rates to direct-to-consumer alternatives. Every statistic cited, every source linked.
Published: March 29, 2026 • Sources: U.S. Census Bureau, CMS, Healthcare Bluebook, Grand View Research
At a Glance
The following statistics represent the most significant data points from our analysis of lab test costs in the United States. Each figure is sourced from public data, government reports, or peer-reviewed market research.
The average American spends approximately $375 per year on laboratory testing services, according to CMS National Health Expenditure data. Total U.S. spending on clinical laboratory services exceeded $124 billion in 2025.
Hospital-based laboratories charge 3 to 10 times more than direct-to-consumer lab services for identical tests processed at the same CLIA-certified facilities. A CBC costs $28–35 online versus $200–500 at a hospital.
An estimated 27.6 million Americans lacked health insurance in 2024, according to the U.S. Census Bureau. These individuals face full chargemaster pricing for lab work with no negotiated discounts.
The direct-to-consumer lab testing market was valued at $3.9 billion in 2024 and is projected to reach $27.8 billion by 2032, reflecting a compound annual growth rate (CAGR) of 15.4%.
Approximately 60% of Americans with employer-sponsored insurance have not met their annual deductible at any given point in the year, meaning they pay full negotiated rates for lab work out of pocket.
2026 Pricing Data
The table below compares 2026 cash-pay prices for 24 of the most commonly ordered lab tests. "Direct Online" prices reflect rates from direct-to-consumer services such as RequestATest. "Hospital Average" prices reflect national average chargemaster rates for uninsured patients, compiled from Healthcare Bluebook, CMS data, and published hospital price transparency files.
| Lab Test | Direct Online Price | Hospital Average |
|---|---|---|
| Complete Blood Count (CBC) | $28–35 | $200–500 |
| Comprehensive Metabolic Panel (CMP-14) | $28–35 | $300–800 |
| Basic Metabolic Panel (BMP-8) | $28–35 | $250–600 |
| Lipid Panel (Cholesterol) | $28–39 | $200–500 |
| Hemoglobin A1C (Diabetes) | $29–39 | $150–400 |
| TSH — Thyroid Screening | $35–49 | $200–500 |
| Full Thyroid Panel (TSH, T3, T4, Free T3, Free T4) | $69–129 | $400–800 |
| Testosterone (Total) | $39–69 | $200–500 |
| Testosterone (Free & Total) | $69–99 | $300–700 |
| Vitamin D (25-Hydroxy) | $35–49 | $100–300 |
| Vitamin B12 | $35–49 | $100–300 |
| Iron Panel with TIBC | $39–59 | $200–400 |
| Ferritin | $29–49 | $100–250 |
| C-Reactive Protein (CRP), High Sensitivity | $35–55 | $100–300 |
| Liver Function Panel (Hepatic) | $28–39 | $200–500 |
| PSA (Prostate-Specific Antigen) | $35–55 | $150–400 |
| Urinalysis | $25–35 | $100–250 |
| STD Panel — 5 Test | $99–149 | $500–1,000 |
| STD Panel — 10 Test (Comprehensive) | $199–299 | $800–1,500 |
| HIV 1/2 Antigen/Antibody (4th Gen) | $49–79 | $150–400 |
| Hepatitis B Surface Antigen | $35–59 | $100–300 |
| Hepatitis C Antibody | $35–59 | $100–300 |
| Drug Test — 10 Panel | $69–99 | $200–500 |
| Comprehensive Wellness Panel (40+ markers) | $149–299 | $1,000–2,500 |
Sources: RequestATest published pricing, Quest Diagnostics direct pricing, Healthcare Bluebook fair price estimates, CMS Clinical Lab Fee Schedule, and hospital price transparency data filed under the CMS Hospital Price Transparency Rule (45 CFR 180). All prices as of March 2026.
Pricing Analysis
The price disparity between hospital-based and direct-to-consumer lab testing is not a reflection of test quality, accuracy, or clinical value. It is a structural artifact of how American hospitals price services. Understanding this system is essential to interpreting lab test cost data.
Every hospital in the United States maintains a chargemaster — a comprehensive list of prices for every billable item and service. Chargemaster prices are not based on the cost of delivering a service. They are set as the starting point for negotiations with insurance companies, which typically negotiate discounts of 60–80% off the list price.
A 2019 study published in JAMA Internal Medicine found that hospital chargemaster prices averaged 3.4 times the Medicare-allowable rate for the same services. For laboratory tests specifically, the markup was even higher. The study examined 2,568 hospitals and found some charging more than 10 times the Medicare rate for routine blood work.
The problem is that uninsured patients are often billed at full chargemaster rates because no insurer is negotiating on their behalf. Even after the 2021 Hospital Price Transparency Rule (45 CFR 180) required hospitals to publish their prices, a 2023 JAMA study found that only 24.5% of hospitals were fully compliant with the rule.
When lab work is performed at a hospital or hospital-affiliated outpatient center, patients are charged a "facility fee" ranging from $50 to $300. This fee covers the hospital's overhead — real estate, utilities, administrative staff, compliance departments — and is charged in addition to the actual cost of the test itself.
A 2022 Health Affairs study found that hospital outpatient facility fees added an average of $182 per visit to patient costs for laboratory services. These fees have increased by approximately 30% over the past decade, even as the underlying cost of performing lab tests has decreased due to automation and technology improvements.
The hospital pricing system creates a feedback loop. Hospitals set high chargemaster prices so they can offer large percentage discounts to insurers. Insurers use these discounts to demonstrate value to their members. Neither party has an incentive to lower the underlying list price, and the actual cost of the service becomes irrelevant to the billing conversation.
According to the CMS Medicare Fee Schedule, the Medicare reimbursement rate for a CBC (CPT code 85025) is approximately $8.67. The actual reagent and labor cost to perform a CBC on modern automated equipment is estimated at $3–5. Hospital chargemaster prices for the same test range from $100 to $500+, representing a markup of 20x to 100x over actual cost.
Key Data Point: According to the CMS Clinical Lab Fee Schedule, Medicare reimburses laboratories $8.67 for a Complete Blood Count. Direct-to-consumer services charge $28–35 (a 3–4x markup over the Medicare rate). Hospitals charge $200–500 (a 23–58x markup over the same Medicare rate). All three use identical CLIA-certified testing methodology.
Market Data
The direct-to-consumer (DTC) laboratory testing market has emerged as one of the fastest-growing segments of the U.S. healthcare industry. Driven by rising out-of-pocket costs, increasing health literacy, and growing consumer demand for convenience, DTC lab testing is reshaping how Americans access routine diagnostics.
According to market research from Grand View Research and Allied Market Research, the key statistics for the DTC lab testing market are:
The DTC lab testing industry has evolved rapidly over the past two decades:
Several factors are fueling DTC lab testing adoption:
Insurance Analysis
The relationship between insurance status and lab test costs is more complex than it appears. Having insurance does not automatically mean lower out-of-pocket costs for lab work — and in many cases, insured patients pay more than they would through direct-to-consumer channels.
The most significant factor affecting out-of-pocket lab costs for insured Americans is the deductible. Key statistics from the Kaiser Family Foundation 2024 Employer Health Benefits Survey:
The practical impact: approximately 60% of Americans with employer-sponsored insurance have not met their deductible at any given point during the year. For these individuals, lab tests ordered through their doctor are billed at the insurer's negotiated rate — which is lower than chargemaster but still significantly higher than direct-to-consumer prices.
Even after insurance negotiation, the in-network rate for lab work typically exceeds direct-to-consumer pricing. Data compiled from insurance Explanation of Benefits (EOB) statements and published allowed amounts shows:
| Test | Direct Online | Insurance Negotiated Rate | Hospital Chargemaster |
|---|---|---|---|
| CBC | $28–35 | $40–120 | $200–500 |
| CMP | $28–35 | $50–150 | $300–800 |
| Lipid Panel | $28–39 | $40–100 | $200–500 |
| TSH | $35–49 | $50–130 | $200–500 |
| Hemoglobin A1C | $29–39 | $40–100 | $150–400 |
Insurance negotiated rates based on published allowed amounts from major insurers and EOB data compiled by Healthcare Bluebook and FAIR Health.
Beyond the negotiated rate, using insurance for lab work carries additional costs that are often overlooked:
STD Testing Data
Sexually transmitted disease testing represents one of the most price-sensitive categories in laboratory diagnostics. Cost is a major barrier to testing — and the price gap between hospital-based and direct-to-consumer STD testing is among the widest of any lab test category.
Data from the CDC's 2024 STD Surveillance Report underscores the scale of STD testing demand in the United States:
The CDC recommends at least annual STD screening for sexually active individuals under 25 and for those with new or multiple partners. Despite these recommendations, a 2023 Kaiser Family Foundation survey found that cost was the primary barrier to STD testing for 34% of uninsured respondents and 19% of insured respondents with high-deductible plans.
| STD Test | Direct Online | Planned Parenthood | Urgent Care / Hospital |
|---|---|---|---|
| Chlamydia & Gonorrhea | $49–79 | $75–200 (sliding scale) | $150–400 |
| HIV (4th Generation) | $49–79 | $0–75 (often free) | $150–400 |
| Syphilis (RPR) | $29–49 | $50–100 | $100–250 |
| Herpes (HSV-1 & HSV-2) | $45–79 | $50–150 | $100–300 |
| Hepatitis B & C | $49–89 | $50–150 | $150–400 |
| 5-Test Panel | $99–149 | $150–350 | $500–1,000 |
| 10-Test Comprehensive Panel | $199–299 | $300–500 | $800–1,500 |
Note: Planned Parenthood uses income-based sliding scale fees. Free or reduced-cost STD testing is available at many public health departments. Hospital prices reflect uninsured cash-pay rates.
The CDC estimates that untreated STDs cost the U.S. healthcare system approximately $16 billion per year in direct medical costs. A significant portion of this burden is attributable to delayed diagnosis driven by cost barriers. When a $99 STD panel is priced at $500–1,000 at a hospital, individuals who might otherwise test regularly defer testing until symptoms become severe — increasing both treatment costs and transmission rates.
Geographic Data
Lab test prices vary significantly by geography. Hospital and clinical laboratory pricing is influenced by state regulations, local market competition, cost of living, insurance market dynamics, and whether a state has adopted price transparency enforcement mechanisms.
Analysis of hospital price transparency data and CMS fee schedules reveals substantial regional differences. The following data represents average hospital chargemaster prices for a standard CBC (CPT 85025) across U.S. regions:
One of the most significant advantages of direct-to-consumer lab testing is geographic price uniformity. Services like RequestATest charge the same price for a CBC whether you are in Manhattan or rural Montana. This is possible because DTC services contract with national laboratory networks (Quest Diagnostics and LabCorp) at standardized rates, eliminating regional hospital pricing dynamics.
For consumers in high-cost regions like the Northeast and West Coast, the savings from direct ordering are even more dramatic. A New York City resident who pays $500 for a CBC at a hospital can order the same test for $28–35 through a DTC service — a savings of over 93%.
It is important to note that not all states permit unrestricted direct-to-consumer lab ordering. As of 2026:
Public Health Data
High lab test costs do not exist in a vacuum. When testing is priced out of reach, individuals defer routine screening — and the downstream costs to both patients and the healthcare system are substantial.
The economic case for affordable lab testing is straightforward. Early detection through routine blood work identifies conditions when they are cheapest to treat:
Methodology
All statistics cited in this report are drawn from publicly available government data, peer-reviewed research, and published market analyses. We prioritize primary sources and clearly identify estimates where exact figures are unavailable.
Note on Pricing Data: Lab test prices are inherently variable. Hospital chargemaster rates represent list prices and do not reflect negotiated rates paid by insured patients. Direct-to-consumer prices are current as of March 2026 and are subject to change. All price ranges represent national averages; individual facility prices may fall outside the ranges cited. We update pricing data quarterly.
Interested in comparing lab test prices for yourself?
Browse current direct-to-consumer pricing across 1,000+ tests and see how they compare to what you have been paying.
View Current Lab Test PricesCommon Questions
Based on CMS National Health Expenditure data, the average American spends approximately $375 per year on laboratory testing services. This figure includes both insured and uninsured patients and covers all types of clinical laboratory testing (blood work, urinalysis, pathology, etc.). Total U.S. spending on clinical laboratory services exceeded $124 billion in 2025. Individual spending varies widely — uninsured patients and those managing chronic conditions often spend significantly more out of pocket.
Hospital lab tests include multiple layers of costs unrelated to the test itself: facility fees ($50–300 per visit), physician interpretation fees, administrative overhead (hospitals spend roughly 25% of revenue on billing and insurance processing), and inflated chargemaster prices that are designed as starting points for insurance negotiation rather than as actual prices. A CBC that costs the laboratory $3–5 in reagents and labor is billed at $200–500 at a hospital. Direct-to-consumer services bypass these markups by sending patients directly to independent lab draw stations at Quest Diagnostics or LabCorp, eliminating facility fees and administrative overhead entirely.
The DTC laboratory testing market is one of the fastest-growing healthcare segments. Valued at approximately $3.9 billion in 2024, market research projects it will reach $27.8 billion by 2032 — a compound annual growth rate (CAGR) of 15.4%. Growth is driven by rising insurance deductibles, increasing numbers of uninsured Americans, greater consumer health awareness, and the normalization of self-directed healthcare that accelerated during the COVID-19 pandemic. The number of DTC lab testing companies has grown from fewer than 10 in 2005 to over 100 as of 2026.